Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia. - Wikidata - awgldk - TriplyDB

Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia.

Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia.

http://www.wikidata.org/entity/Q37609307

about

Quality assessment of economic analyses of pharmacological and nutritional therapy for hyperlipidemia.

http://www.wikidata.org/entity/Q37609307

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2002

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Quality assessment of economic ...... al therapy for hyperlipidemia.

@en

Quality assessment of economic ...... al therapy for hyperlipidemia.

@nl

type

label

Quality assessment of economic ...... al therapy for hyperlipidemia.

@en

Quality assessment of economic ...... al therapy for hyperlipidemia.

@nl

prefLabel

Quality assessment of economic ...... al therapy for hyperlipidemia.

@en

Quality assessment of economic ...... al therapy for hyperlipidemia.

@nl

P1433

Q37609307-34FF5C3C-40EB-427B-AA4A-5C8F96B79BA4

P1476

Q37609307-140B1D1E-39D5-4FFF-9075-7D094CE261A7

P2093

Q37609307-4EA7A6C6-D128-4392-A97B-D412DFB03BF4

Q37609307-5FF451A6-0D82-474E-B8BC-D27DEEBF27C6

Q37609307-723078CB-286C-4CF5-A116-D0CF41C456DD

P2860

Q37609307-0BF1267E-6DC5-4DE1-86D8-5E7861095B44

Q37609307-1081C2E7-8C81-4EAE-84CD-F0A0BC78690E

Q37609307-2C311206-9357-4DDD-A2E7-C4307741C4CE

Q37609307-30853763-520F-48AE-B344-EF76DB55FF52

Q37609307-5A614722-B51F-4ACB-8A0C-ADB7B0E3CB2F

Q37609307-694461E4-3D51-4C09-B1AD-CD89EE45B8B2

Q37609307-76BEF526-5468-4DF0-9D78-9BD8D79BB23A

Q37609307-7FC76C0E-4424-4AF7-AB75-33457C73E7E0

Q37609307-82077CDC-ED34-4F94-9891-096048D175D8

Q37609307-C332ED1B-66C1-46E1-86DE-C68969C0E97D

P304

Q37609307-21D46E52-5326-48B5-8429-BADCC716188E

P31

Q37609307-C7952AB7-F7B4-4703-BFCC-154A2922425E

P356

Q37609307-A2F60621-0A32-43FF-9D0D-BE5BF8A8ACEA

P433

Q37609307-E5DF693F-F414-4840-B753-635A809B2532

P478

Q37609307-5FB42FC5-1EBD-4137-AAEE-C234C642E5D6

P577

Q37609307-A2AC4921-2A75-4268-856D-5A37175EF1B0

P698

Q37609307-CABD4224-841E-456F-9ADF-B34E9987CEF7

P921

Q37609307-06E10BD6-3B8B-42EB-B813-CBAA5DDD8994

Q37609307-62E3A99A-63B8-455B-941A-42C166A1B854

P356

14737167.2.6.565

P1433

Expert Review of Pharmacoeconomics & Outcomes Research

P1476

Quality assessment of economic ...... al therapy for hyperlipidemia.

@en

P2093

Dennis W Raisch

http://www.w3.org/2001/XMLSchema#string

Matthew E Borrego

http://www.w3.org/2001/XMLSchema#string

Ritesh N Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance.

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.

The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholester

A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.

A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).

Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease.

Economic analysis alongside clinical trials. Revisiting the methodological issues.

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

P304

565-575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737167.2.6.565

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19807481

http://www.w3.org/2001/XMLSchema#string

P921